Pricing Log in Create free account

Bright Minds Biosciences Inc. (DRUG) vs Protalix BioTherapeutics, Inc. (PLX)

Bright Minds Biosciences Inc. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. Bright Minds Biosciences Inc. is the larger, with a market value of $226.9M against $204.7M — 1.1× the size. Bright Minds Biosciences Inc. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.6×. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 13 metrics below, Protalix BioTherapeutics, Inc. leads on 9 and Bright Minds Biosciences Inc. on 4.

Valuation

Metric DRUG PLX Biotechnology median
P/E n/m 10.58 10.60
P/S n/m 2.52 9.40
P/B 1.02 2.85 2.13
Price to free cash flow n/m 26.50 25.18
EV/EBITDA n/m 7.32 0.66
EV/Sales n/m 2.26 9.02
Earnings yield (9.04%) 9.45% (32.88%)
Free cash flow yield (7.85%) 3.77% (23.13%)

Profitability

Metric DRUG PLX Biotechnology median
Gross margin 0.00% 69.20% 68.51%
Operating margin 0.00% 28.89% 0.00%
Net margin 0.00% 23.50% 0.00%
Free cash flow margin 0.00% 9.51% 0.00%
Return on equity (13.64%) 31.23% (51.96%)
Return on assets (13.52%) 20.07% (46.06%)
Return on invested capital 0.00% 48.48% 0.00%

Growth

Metric DRUG PLX Biotechnology median
Revenue growth (TTM) — 30.14% 6.76%
EPS growth (last fiscal year) (164.58%) (300.00%) 29.88%
Revenue growth, 5-year CAGR — (3.46%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRUG PLX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 121.98 2.94 4.97
Net debt to EBITDA 5.98 7.68 1.01

Dividend

Metric DRUG PLX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DRUG PLX Biotechnology median
Market cap 226.87m 204.65m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack